C3G & IC-MPGN: Rare Kidney Diseases – Symptoms, Diagnosis & Treatment

Rare kidney diseases, C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN), are increasingly understood thanks to advances in complement inhibitor therapies. Both conditions involve dysfunction in the complement system – a crucial part of the immune response – leading to inflammation and potential kidney failure. Even as distinct in their underlying mechanisms, they share overlapping symptoms and pose a significant challenge to diagnosis and treatment. Up to half of those diagnosed may develop kidney failure within a decade, highlighting the urgency of ongoing research and improved therapeutic options.

Understanding the Complement System and Kidney Damage

The kidneys filter waste and excess fluid from the blood through tiny networks called glomeruli. In both C3G and IC-MPGN, the complement system becomes overactive, triggering inflammation and damage to these vital filters. This disruption leads to protein and blood appearing in the urine, swelling in the body, and potentially, a decline in kidney function. The precise way the complement system malfunctions differs between the two diseases. In C3G, the problem centers around the C3 protein, while IC-MPGN involves a broader immune complex deposit including both antibodies and complement proteins. Healthline provides a helpful overview of these distinctions.

Recognizing the Signs and Symptoms

Early stages of both C3G and IC-MPGN often present with few or no noticeable symptoms. As kidney damage progresses, however, several signs may emerge. These include blood in the urine (hematuria), which can range from barely visible to a noticeable pink or red tinge; excessive protein in the urine (proteinuria), sometimes causing foamy or cloudy urine; reduced urine production (oliguria); swelling in the legs, ankles, hands, or around the eyes (edema); high blood pressure (hypertension); fatigue; nausea and vomiting; and even muscle spasms, particularly at night. A less common symptom specific to C3G is acquired partial lipodystrophy, an abnormal distribution of fat under the skin. Some individuals with C3G may develop drusen, small yellow deposits in the retina.

What Causes These Rare Kidney Diseases?

Both IC-MPGN and C3G stem from a malfunctioning complement system, resulting in deposits within the kidney’s filtering system. In C3G, the breakdown of complement proteins, particularly C3, leads to inflammation and damage. IC-MPGN involves deposits of both C3 and other immune proteins. The root cause of this dysfunction isn’t fully understood, but genetic factors and autoimmune responses play a role. Approximately a quarter of C3G patients have genetic mutations affecting complement regulation. IC-MPGN can also be linked to other conditions, such as autoimmune diseases like lupus and rheumatoid arthritis, chronic infections like hepatitis B or C and HIV, certain cancers, and sickle cell disease. Kidney International Reports details these connections.

Diagnosis: A Multi-Step Process

Diagnosing C3G and IC-MPGN can be challenging due to the nonspecific nature of early symptoms. The process typically begins with blood and urine tests to assess kidney function and detect abnormalities. However, a kidney biopsy is essential for definitive diagnosis. This involves examining a small tissue sample under a microscope, using a technique called immunofluorescence microscopy to differentiate between C3G, IC-MPGN, and other similar disorders. Further testing, including advanced complement system analysis and genetic testing, may be conducted to guide treatment decisions.

Emerging Treatment Options and Medications

Historically, treatment for C3G and IC-MPGN focused on managing symptoms and suppressing the immune system. However, recent advances have introduced targeted therapies addressing the underlying complement dysfunction. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are commonly used to control blood pressure and reduce protein in the urine. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed for diabetes, are also showing promise in protecting kidney function. Immunosuppressive therapies, such as prednisone and mycophenolate mofetil, may be used to calm an overactive immune system.

The most significant breakthrough lies in complement inhibitors. Iptacopan (Fabhalta) was approved in March 2025 for C3G, while pegcetacoplan (Empaveli) received approval in July 2025 for both C3G and IC-MPGN. These medications directly target the complement system, reducing inflammation and stabilizing kidney function. Eculizumab (Soliris) has also been used off-label, and further complement inhibitors are currently under investigation in clinical trials. Plasma exchange, a blood filtering process, may be considered for rapidly progressing cases. In advanced stages, dialysis or kidney transplantation may be necessary. Anticomplement Therapies for C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis provides a detailed overview of these therapies.

Lifestyle Adjustments for Kidney Health

Alongside medical treatment, lifestyle modifications can significantly impact disease management. A kidney-friendly diet, low in salt and protein, can help reduce inflammation and preserve kidney function. Maintaining a healthy weight, choosing heart-healthy foods, and minimizing alcohol intake are also crucial. Regular exercise is beneficial, but it’s essential to consult with a healthcare team before starting any latest program. Consistent follow-up appointments with regular blood and urine tests are vital for monitoring kidney function and adjusting treatment as needed.

Looking Ahead: Prognosis and Support

C3G and IC-MPGN are chronic conditions with no current cure. Treatment aims to gradual disease progression and prevent kidney failure. However, up to half of patients may still progress to finish-stage renal disease within 10 years, requiring dialysis or transplantation. Prognosis varies depending on factors like genetic mutations, the presence of autoantibodies, and the severity of kidney damage at diagnosis. Early diagnosis, effective blood pressure control, and adherence to treatment plans are key to improving outcomes.

Resources like NephCure offer support and information for individuals and families affected by these rare kidney diseases. Ongoing research continues to explore new therapeutic targets and improve our understanding of these complex conditions. The future of C3G and IC-MPGN treatment hinges on continued innovation in complement inhibition and personalized medicine approaches.